F
Frank M. Sacks
Researcher at Harvard University
Publications - 520
Citations - 86842
Frank M. Sacks is an academic researcher from Harvard University. The author has contributed to research in topics: Cholesterol & Weight loss. The author has an hindex of 120, co-authored 490 publications receiving 80422 citations. Previous affiliations of Frank M. Sacks include Erasmus University Rotterdam & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
Frank M. Sacks,Hannia Campos +1 more
TL;DR: Because the classical lipid risk factors by no means perfectly predict CHD in patients, lipoprotein subfractionation has the potential to improve risk prediction.
Journal ArticleDOI
Relation Between Alkaline Phosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality
Marcello Tonelli,Gary C. Curhan,Marc A. Pfeffer,Frank M. Sacks,Ravi Thadhani,Michal L. Melamed,Natasha Wiebe,Paul Muntner +7 more
TL;DR: An independent relation between higher levels of AlkP and adverse outcomes among survivors of myocardial infarction and in a general population sample is found.
Journal ArticleDOI
Plasma Phospholipid Long-Chain ω-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults: A Cohort Study
Dariush Mozaffarian,Rozenn N. Lemaitre,Irena B. King,Xiaoling Song,Hongyan Huang,Frank M. Sacks,Eric B. Rimm,Molin Wang,David S. Siscovick +8 more
TL;DR: In this paper, the effects of adding supplements to background dietary intake and secondary prevention were evaluated for dietary n-3 polyunsaturated fatty acids (n3-PUFA) or primary prevention.
Journal ArticleDOI
Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure
TL;DR: It is concluded that oat bran has little cholesterol-lowering effect and that high-fiber and low- fiber dietary grain supplements reduce serum cholesterol levels about equally, probably because they replace dietary fats.
Journal ArticleDOI
Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) trial
Sandra J. Lewis,Frank M. Sacks,Jayne Mitchell,Cara East,Stephen P. Glasser,Sheren Kell,Rebecca Letterer,Marian C. Limacher,Lemuel A. Moyé,Jean L. Rouleau,Marc A. Pfeffer,Eugene Braunwald +11 more
TL;DR: Pravastatin led to significant early reduction of a wide range of cardiovascular events in post-MI women with average cholesterol levels and improved plasma lipids similarly in men and women.